Ipilimumab + Temozolomide in Metastatic Melanoma

2014-08-27 03:13:52 | BioPortfolio


The goal of this clinical research study is to learn if combining Ipilimumab and Temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied. Researchers would also like to study how this therapy affects the levels of certain chemicals in the blood that are related to your immune system.


The ability to control melanoma depends on how well your immune system recognizes and then attacks cancer cells. Researchers want to use Ipilimumab to try to trigger your immune system response, while Temozolomide is designed to damage the cancer cells themselves.

Study Drugs:

Ipilimumab is designed to block the activity of cells that lower the immune system's ability to fight cancer. Blocking these cells may help the body's immune system fight the cancer cells better.

Temozolomide is designed to stop cancer cells from making new DNA (the genetic material of cells). If they cannot make DNA, then they cannot divide into new cancer cells.

Screening Tests:

Signing this consent form does not mean that you will be able to take part in this study. You will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests and procedures will be performed within 14 days before you begin receiving the study drugs:

- You will have your complete medical history recorded.

- You will also be asked about any symptoms you are experiencing and any medication you are taking.

- You will have a complete physical exam, including measurement of your height, weight, and vital signs (temperature, heart rate, breathing rate, and blood pressure).

- You will be asked how well you are able to perform the normal activities of daily living (performance status evaluation).

- Blood (about 2 teaspoons) will be collected for routine blood tests.

- You will have an electrocardiogram (ECG--a test to measure the electrical activity of the heart).

- You will have several scans to check the status of the disease, including a chest X-ray, a magnetic resonance imaging (MRI) scan of the brain, and a computed tomography (CT) scan of the chest, abdomen, and pelvis.

- If you have breathing problems, you will have a breathing test to measure how much air your lungs can hold and how much air you can exhale.

- Women who are able to become pregnant must have a negative blood (about 1 teaspoon) or urine pregnancy test within 72 hours (3 days) before the start of ipilimumab therapy.

The study doctor will discuss the screening test results with you. If the screening tests show that you are not eligible to take part in the study, you will not be enrolled. Other treatment options will be discussed with you.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will begin to receive treatment with ipilimumab plus temozolomide. You will have a central venous catheter (CVC) placed before you begin receiving treatment. A central venous catheter is a sterile flexible tube that will be placed into a large vein while you are under local anesthesia. Your doctor will explain this procedure to you in more detail, and you will be required to sign a separate consent form for this procedure.

There are 2 phases of study drug treatment: Induction and Maintenance.

During the Induction Phase, you will receive ipilimumab by vein over 90 minutes on Day 1 of each 3-week Induction "course." You will take temozolomide by mouth in tablet form on Days 1-4 of each course. You will receive up to 4 courses of Induction therapy.

During the Maintenance Phase, you will receive ipilimumab by vein over 90 minutes on Day 1 every 12 weeks. You will also take temozolomide by mouth for 5 days in a row, every 4 weeks.

You will see your doctor before each new course (every 3 weeks) during the Induction Phase, and once every 4 weeks during the Maintenance Phase. All treatments will be given in the outpatient clinic. You will be given anti-nausea medication to decrease the risk of nausea and vomiting, as needed.

Study Tests:

Before Each Course:

(Every 3 weeks during Induction, and every 4 weeks during Maintenance)

- Blood (about 1 teaspoon) will be drawn for routine tests.

- You will be asked about any medication you are taking and any side effects you are experiencing.

- Women who are able to become pregnant will have a blood (about 1 teaspoon) or urine pregnancy test.

- Your performance status will be recorded.

- Your vital signs will be measured on Day 1.

Every week, blood (about 1 teaspoon) will be drawn for routine tests and tests of your liver and kidney function.

At the end of each course, any tumor that can be felt with the hands will be measured during physical exam to see if it is shrinking.

Every 2 courses, you will have a chest x-ray and CT or MRI scans performed to check the status of the disease.

Length of Study:

You may continue taking the study drugs for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drugs if the disease gets worse or intolerable side effects occur.

If you stop receiving the study drugs for any reason, you will have an End-of-Treatment Visit.

End-of-Treatment Visit:

Within 14 days after you stop study treatment, you will come into the clinic for the End-of-Treatment Visit. At this visit, the following tests will be performed:

- You will have a physical exam, including a measurement of your vital signs and weight.

- You will be asked about any other medications you are taking or any side effects you are experiencing.

- Blood (about 2 tablespoons) will be drawn for routine tests.

- Your may have a CT or MRI scan performed to check for side effects.

Every 2 months for up to 3 years, you will also be contacted by telephone or during a clinic visit to see how you are doing.

Additional Study Instructions:

- You must follow all instructions and directions you are given while on study.

- You must tell your doctor about any medication, over-the-counter products, herbal remedies, or alternative therapies that you use while you are on this study.

- You should not have any immunizations (vaccinations) without telling your doctor first.

- You should not donate blood while on study or for 70 days after your last dose of the study drugs.

- You must tell your doctor about any medical treatments that you will have during the study (such as elective surgery).

This is an investigational study. At this time, temozolomide is FDA approved and commercially available for the treatment of primary brain cancer. However, the use of temozolomide in treating metastatic melanoma is considered investigational. At this time, ipilimumab is being used in research only. The use of these drugs together is also considered investigational.

Up to 64 patients will take part in this study. All will be enrolled at M. D. Anderson.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Metastatic Melanoma


Ipilimumab, Temozolomide


UT MD Anderson Cancer Center
United States




M.D. Anderson Cancer Center

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:13:52-0400

Clinical Trials [1872 Associated Clinical Trials listed on BioPortfolio]

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with the drugs Temodar (temozolomide), ...

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimu...

A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

The purpose of this study is to evaluate the efficacy of ABT-888 in combination with Temozolomide versus Temozolomide alone in subjects with metastatic melanoma.

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called pa...

PubMed Articles [2271 Associated PubMed Articles listed on BioPortfolio]

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma ...

Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.

Immune checkpoint inhibitors are new therapeutic options for metastatic melanoma, but little data is available in organ transplant recipient populations. Six French patients, 3 men and 3 women, mean a...

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.

Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting...

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.

A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival ...

F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma.

Immune checkpoint inhibitors (ICIs) are now commonly used to treat patients with metastatic malignant melanoma. While concerns have been raised that the inflammatory response induced by ICIs may limit...

Medical and Biotech [MESH] Definitions

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

More From BioPortfolio on "Ipilimumab + Temozolomide in Metastatic Melanoma"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Searches Linking to this Trial